金斯瑞生物科技：2024年集团收益5.945亿美元 增长6.1%

Core Insights - The company reported a revenue increase to approximately $594.5 million for the year ending December 31, 2024, representing a 6.1% growth from about $560.5 million in 2023, driven by enhanced brand influence in the European and American markets and the introduction of new services and products [1] - The company achieved a significant profit turnaround, moving from a loss of approximately $355.1 million in 2023 to a profit of about $2.9 billion in 2024, largely due to the demerger of its cell therapy business [1] - Adjusted net profit from continuing operations grew by 2.9% to approximately $59.8 million [1] Revenue Composition - Life sciences services and products accounted for 75.8% of total revenue, biopharmaceutical development services made up 14.8%, and industrial synthetic biology products represented 9.0% [1] Expense Analysis - Sales and distribution expenses increased by 10.0% to approximately $88.1 million, attributed to increased marketing efforts and investment in commercial talent [1] - Administrative expenses rose by 7.1% to about $114.4 million, mainly due to capacity expansion and enhanced administrative functions [1] - Research and development expenses grew by 2.1% to approximately $53.8 million [2]